Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Other Non-Current Assets (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Other Non-Current Assets for 6 consecutive years, with $5.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets fell 3.46% year-over-year to $5.2 million, compared with a TTM value of $5.2 million through Dec 2025, down 3.46%, and an annual FY2025 reading of $5.2 million, down 3.46% over the prior year.
  • Other Non-Current Assets was $5.2 million for Q4 2025 at Xeris Biopharma Holdings, down from $5.3 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $5.5 million in Q2 2024 and bottomed at $211000.0 in Q3 2021.
  • Average Other Non-Current Assets over 5 years is $4.1 million, with a median of $4.8 million recorded in 2022.
  • The sharpest move saw Other Non-Current Assets surged 928.44% in 2022, then decreased 7.86% in 2025.
  • Year by year, Other Non-Current Assets stood at $829000.0 in 2021, then skyrocketed by 470.57% to $4.7 million in 2022, then fell by 4.02% to $4.5 million in 2023, then increased by 19.1% to $5.4 million in 2024, then fell by 3.46% to $5.2 million in 2025.
  • Business Quant data shows Other Non-Current Assets for XERS at $5.2 million in Q4 2025, $5.3 million in Q3 2025, and $5.1 million in Q2 2025.